Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Xiawei Wei"'
Publikováno v:
Journal of Hematology & Oncology. 15
Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and infla
Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin
Autor:
Yuan Cheng, Xuejiao Han, Qingfang Li, Fei Mo, Xiawei Wei, Yuquan Wei, Houhui Shi, Siyuan Chen
Publikováno v:
Molecular Cancer, Vol 20, Iss 1, Pp 1-21 (2021)
Molecular Cancer
Molecular Cancer
Background Drug-resistance and severe side effects of chemotherapeutic agents result in unsatisfied survival of patients with lung cancer. CXCLs/CXCR2 axis plays an important role in progression of cancer including lung cancer. However, the specific
Publikováno v:
Annals of Surgical Oncology
Surgical resection is a common therapeutic option for primary solid tumors. However, high cancer recurrence and metastatic rates after resection are the main cause of cancer related mortalities. This implies the existence of a “fertile soil” foll
Autor:
Zhe Zhang, Siyuan Qin, Yan Chen, Li Zhou, Mei Yang, Yongquan Tang, Jing Zuo, Jian Zhang, Atsushi Mizokami, Edouard C Nice, Hai‐Ning Chen, Canhua Huang, Xiawei Wei
Publikováno v:
EMBO Molecular Medicine, Vol 14, Iss 2, Pp n/a-n/a (2022)
Entering a drug‐tolerant persister (DTP) state of cancer cells is a transient self‐adaptive mechanism by which a residual cell subpopulation accelerates tumor progression. Here, we identified the acquisition of a DTP phenotype in multidrug‐resi
Autor:
Yong Peng, Shengyong Yang, Wenchen Pu, Jian-Kang Zhou, Xin Fan, Yuanyuan Zheng, Ke Wu, Yun Zhao, Yuquan Wei, Yu-Zhu Zheng, Rui Ma, Chun Wang, Xiawei Wei, Huaiyu He, Juan He, Xuesha Liu
Publikováno v:
Cancer Letters. 458:76-85
Limited drug response and severe drug resistance confer the high mortality of non-small-cell lung cancer (NSCLC), a leading cause of cancer death worldwide. There is an urgent need for novel treatment against NSCLC. Receptor tyrosine kinase-like orph
Autor:
Edouard C. Nice, Li Zhou, Wei Gao, Changlong Li, Yujia He, Junhong Han, Yunlong Lei, Zhe Zhang, Lu Zhang, Hai-Ning Chen, Xiawei Wei, Canhua Huang, Siyuan Qin, Zong-Guang Zhou, Jiayang Liu, Yan Chen
Publikováno v:
Theranostics
Rationale: The sustained and severe endoplasmic reticulum (ER) stress in cancer cells may contribute to apoptotic cell death, thus representing a potential target for cancer therapy. Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor approve
Publikováno v:
Nano Letters. 19:2905-2913
Multidrug resistance (MDR) is still a formidable obstacle for the majority of anticancer drugs during chemotherapy. MDR is generally divided into the pump and nonpump resistances, which significantly and simultaneously reduce drug accumulation and po
Autor:
Li Liu, Wen Nie, Yu Jiang, Chengjian Zhao, Yanping Qian, Tao Yi, Jingyun Yang, Jia Geng, Xiao Liang, Xiawei Wei, Xia Zhao
Publikováno v:
ACS Applied Materials & Interfaces. 10:32006-32016
Cationic nanocarriers are reported to induce cell necrosis, especially in the lungs upon systemic administration. The release of damage-associated molecular patterns, such as mitochondrial DNA from the injured cell may result in the inflammatory toxi
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 18, Iss 1, Pp 1-22 (2019)
Molecular Cancer, Vol 18, Iss 1, Pp 1-22 (2019)
Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). The Gas6/AXL signalling pathway is associated with tumour cell gro
Publikováno v:
Biomaterials. 106:119-133
Patients suffering from cancer have benefited from combination therapy. Nanocarriers are the ideal candidates for combination therapy. In this study, we constructed docetaxel (DTX) loaded micellar nanomedicines co-loaded with near infrared (NIR) dye-